Core Insights - The strategic partnership between Meinian Health and Aihuilong aims to integrate advanced in vitro diagnostic technology with a vast health examination network and AI health management platform to enhance disease screening efficiency and preventive medicine levels [1][2] Group 1: Partnership Objectives - The collaboration focuses on building a comprehensive health management service system that spans prevention, diagnosis, treatment, and management, aligning with national health management guidelines [2][3] - Meinian Health's Chairman emphasized that this partnership is a significant milestone in deepening health service capabilities and enhancing professional barriers [2] Group 2: Specific Areas of Focus - Aihuilong will assist Meinian Health in customizing autoimmune disease screening packages tailored to different examination populations, enabling early identification and risk warning for high-risk individuals [3] - The partnership will establish a comprehensive management system for high-risk cardiovascular patients, integrating prevention, diagnosis, treatment, and management into a closed-loop healthcare pathway [3] Group 3: Future Vision - The collaboration aims to create a continuously evolving and collaboratively innovative health management ecosystem that provides proactive health management services across the entire life cycle [4] - This initiative supports the national chronic disease prevention strategy and contributes to the broader "Healthy China" vision through industry innovation [4]

Core Insights - The article reports on a strategic cooperation agreement signed between Aihuilong and Meinian Health on December 29, aimed at integrating advanced in vitro diagnostic technology with a vast health examination network and AI health management platform [1] Group 1: Strategic Partnership - Aihuilong and Meinian Health are collaborating to enhance disease screening efficiency and preventive medicine levels [1] - The partnership focuses on exploring data-driven disease risk model construction and optimizing personalized health management solutions [1] - The goal is to create a closed-loop health management pathway through the integration of their respective technologies and platforms [1]

（文章来源：证券日报） 证券日报网讯 12月29日，美年健康在互动平台回答投资者提问时表示，公司股东人数请详见公司的定 期报告。 ...

Group 1 - The "2025 Responsibility Shine Qilu" annual health event highlighted the importance of health management and recognized outstanding contributions in the healthcare sector [1] - The event announced the "Top Ten Health News in Shandong" and awarded titles such as "Responsible Hospital," "Responsible Department," and "Responsible Medical Practitioner" [1] - The launch of the "Yidian Ask Doctor" digital doctor service and the initiation of the "Yidian Ask Doctor" national health protection series for 2026 were also key highlights of the event [1] Group 2 - Meinian Health Industry (Shandong) Co., Ltd. was established in 2015 and is part of Meinian Health Industry Holdings Co., Ltd., a leading private healthcare enterprise in China [3] - The company operates under three health examination brands: "Mienian Health," "Ciming," and "Ciming Aoya," with over 40 examination centers across 16 cities in Shandong [3] - Meinian Health serves nearly 3 million health examination clients annually, focusing on health consultation, assessment, and management, supported by a vast network and health data [3]

Group 1 - The National Venture Capital Guidance Fund has officially launched, focusing on early-stage investments in sectors such as integrated circuits, artificial intelligence, aerospace, and low-altitude economy [1][3] - The fund aims to mobilize nearly 1 trillion yuan in local and social capital through its establishment [3] - Three regional sub-funds have been established in Beijing, Shanghai, and Shenzhen, with total scales of 296.46 billion yuan, 471 billion yuan, and 450.5 billion yuan respectively [3] Group 2 - The fund features a three-tier structure: national mother fund, regional mother funds, and sub-funds, with a 20-year duration to promote "patient capital" [4] - Sub-funds are required to invest 70% of their capital in seed and early-stage projects, without regional reinvestment obligations [4] - The private equity and venture capital market is expected to see a significant increase, with a 37.42% year-on-year growth in new registered funds by Q3 2025 [4] Group 3 - State-owned capital dominates the LP market with an investment of 123.12 billion yuan, accounting for 46.8% of total contributions [5] - Corporate investors contribute 44.15 billion yuan, representing 16.8% of the total, primarily from industrial groups and listed companies [5] - Nearly 300 listed companies have engaged in or are planning to establish investment funds this year [5] Group 4 - Companies like Meinian Health and Binhua Co. are actively participating in venture capital by establishing or investing in funds focused on AI, automation, and strategic emerging industries [6][7] - The investment strategies of these companies aim to enhance their competitive edge and align with their long-term strategic goals [6][7] - The establishment of investment funds by listed companies is seen as a way to expand business opportunities and leverage professional investment capabilities [9]

Group 1 - The company announced that its wholly-owned subsidiary, Meinian Chuangxin, signed a share transfer agreement to acquire a 16.6667% limited partnership interest in the Guangzhou Qiaoxin Shengjing No.1 Venture Capital Partnership, corresponding to a subscribed capital contribution of RMB 10 million, with a paid-in capital of RMB 0 [1] - The total subscribed capital contribution for the partnership is RMB 60 million, with Meinian Chuangxin contributing RMB 10 million, representing 16.6667% of the total [1] - The investment is part of the company's "ALL in AI" strategy, aimed at leveraging professional investment operations to seize opportunities in AI technology and key industry applications, enhancing overall competitiveness and promoting long-term development [2]

Group 1 - The company announced that its wholly-owned subsidiary, Meinian Chuangxin, signed a share transfer agreement to acquire a 16.6667% limited partnership interest in the Guangzhou Qiaoxin Shengjing No.1 Venture Capital Partnership, corresponding to a subscribed capital contribution of RMB 10 million, with a paid-in capital of RMB 0 [1] - The total subscribed capital contribution for the partnership is RMB 60 million, with Meinian Chuangxin contributing RMB 10 million, representing 16.6667% of the total [1] - The investment is part of the company's "ALL in AI" strategy, aimed at leveraging professional investment operations to seize opportunities in AI technology and key industry applications, enhancing overall competitiveness and promoting long-term development [2]

关于下属全资子公司受让股权投资基金份额 暨与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资概述 近日，美年大健康产业控股股份有限公司（以下简称"公司"）下属全资子公 司美年创信（上海）企业管理有限公司（以下简称"美年创信"）与广州华诚数财 信息科技有限公司（以下简称"华诚数财"）签署了《广州侨鑫胜璟一号创业投资 合伙企业（有限合伙）份额转让协议书》（以下简称"份额转让协议"），拟受让 华诚数财所持有的广州侨鑫胜璟一号创业投资合伙企业（有限合伙）（以下简称 "胜璟一号基金"或"合伙企业"）16.6667%的有限合伙份额，对应的认缴出资额为 人民币 1,000 万元，实缴出资额为人民币 0 元。同时，美年创信与广州胜璟创业 投资有限公司（以下简称"胜璟创投"）、四川璞信产融投资有限责任公司（以下 简称"璞信产融"）、佛山市三水区金融投资控股有限公司（以下简称"三水金投"）、 侨银城市管理股份有限公司（以下简称"侨银股份"）、华诚数财签署了《广州侨 鑫胜璟一号创业投资合伙企业（有限合伙）之合伙协议》（以下简称" ...

Core Viewpoint - The company is collaborating with leading enterprises in precision diagnosis and embodied intelligence to create a comprehensive health management model through "health check centers + home services" and "AI proactive health centers" [1] Group 1: Strategic Partnerships - On December 19, 2025, the company signed a strategic cooperation agreement with Shengxiang Bio, a leader in precision diagnosis, to develop a dual-service system combining health check centers and home services, establishing a digital health management loop [2][3] - The company showcased the "AI Proactive Health Center" in collaboration with Hong Kong's first embodied intelligent robot company, which includes various products such as robot nurses and smart health monitoring tools [4] Group 2: Product Development and Revenue Growth - The company is promoting specialized products like cardiopulmonary screening and AI-MDT reports, achieving approximately 250 million yuan in revenue from AI-related products in the first three quarters of 2025, a year-on-year increase of 71.02% [5] - The launch of the "Hematological Clock," an AI aging assessment product, is expected to further enhance AI-related revenue by utilizing extensive health data [5] Group 3: Customer Acquisition and Service Optimization - The company is implementing a "dual-wheel drive" strategy of group and individual health checks, increasing the proportion of individual customers contributing to revenue from 24.1% in 2024 to 33% [6] - The company is expanding its health management services, including weight management clinics, to create a complete health management loop from screening to intervention [6] Group 4: Future Outlook - For Q4 and next year, the company anticipates stable increases in customer spending through specialized products and improved customer acquisition strategies, while also enhancing operational efficiency through management tools [7] - Revenue projections for 2025-2027 are estimated at 10.636 billion, 11.538 billion, and 12.818 billion yuan, with net profits expected to grow significantly [8]

资金流向方面，深港通医疗（983035）指数成份股当日主力资金净流出合计4.68亿元，游资资金净流入 合计7872.44万元，散户资金净流入合计3.9亿元。成份股资金流向详情见下表： 证券之星消息，12月22日，深港通医疗（983035）指数报收于4484.9点，跌0.43%，成交109.25亿元， 换手率1.59%。当日该指数成份股中，上涨的有22家，楚天科技以8.04%的涨幅领涨，下跌的有35家， 美年健康以6.75%的跌幅领跌。 深港通医疗（983035）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近10日内深港通医疗（983035）指数成份股做了调整，新纳入了2只股票。 ...